The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR–ABL tyrosine kinase inhibitors
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR–ABL tyrosine kinase inhibitors
Authors
Keywords
-
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 61, Issue 2, Pages 193-202
Publisher
Springer Nature
Online
2011-08-26
DOI
10.1007/s00262-011-1096-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study
- (2010) Giuseppe Saglio et al. CANCER
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
- A chemical and phosphoproteomic characterization of dasatinib action in lung cancer
- (2010) Jiannong Li et al. Nature Chemical Biology
- The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
- (2010) Taro Kawai et al. NATURE IMMUNOLOGY
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- (2010) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
- (2010) Giuseppe Saglio et al. NEW ENGLAND JOURNAL OF MEDICINE
- The DC-HIL/syndecan-4 pathway inhibits human allogeneic T-cell responses
- (2009) Jin-Sung Chung et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Resolution of Rheumatoid Arthritis Symptoms With Imatinib Mesylate
- (2009) Matthew R. Vernon et al. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
- Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
- (2009) A Hochhaus et al. LEUKEMIA
- Tyrosine kinases as targets for the treatment of rheumatoid arthritis
- (2009) Christina D'Aura Swanson et al. Nature Reviews Rheumatology
- Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study
- (2009) Jacques Tebib et al. ARTHRITIS RESEARCH & THERAPY
- Cancer Immunotherapy by Dendritic Cells
- (2008) Cornelis J.M. Melief IMMUNITY
- Tyrosine kinases as targets in rheumatoid arthritis
- (2008) Antonio G. Tristano INTERNATIONAL IMMUNOPHARMACOLOGY
- Maintained Efficacy of the Tyrosine Kinase Inhibitor Imatinib Mesylate in a Patient With Rheumatoid Arthritis
- (2008) Kari K. Eklund et al. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
- Post-transcriptional regulation of adapter molecules by IL-10 inhibits TLR-mediated activation of antigen-presenting cells
- (2008) A Knödler et al. LEUKEMIA
- Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib
- (2008) Oliver Hantschel et al. LEUKEMIA & LYMPHOMA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now